Genenta reports long-term survival trends in brain tumor trial

Genenta Science announced an update from its ongoing phase 1/2a TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter.

According to Genenta, as of the November 21, 2025 data cut, 25 patients have been treated with Temferon, the company’s genetically modified, autologous hematopoietic stem cell-based platform designed to deliver IFNa, specifically into the TME via Tie-2 expressing monocytes.

More than seven months after the prior update, key survival metrics for the TEM-GBM patients remain consistent. 44% of patients have reached 18-month survival, compared to 38% reported in April. Two-year survival rate continues to be 29% and median overall survival remains at 17 months, both consistent with prior findings. The study includes the first patient who has reached three years of survival following Temferon administration without receiving additional therapeutic interventions or second-line treatments.

Standard therapy for GBM — a highly malignant brain tumor — involves surgical resection, followed by radiotherapy plus temozolomide (TMZ) therapy. Patients with an uMGMT gene promoter have an even worse prognosis because they are resistant to TMZ.

Temferon, a lentivirus immunotherapy based on hematopoietic stem progenitor cells, enables controlled and targeted IFNa expresssion within the tumor microenvironment of solid tumors. According to Genenta, Temferon’s unique potential to reprogram the tumor microenvironment not only enhances the potential efficacy of Temferon as a monotherapy but also suggests promising synergies when combined with various immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies.

Earlier this year, Genenta amended its agreement with AGC Biologics to include an exclusive GMP suite at the CDMO’s Cell and Gene Center of Excellence in Milan, which Genenta will use to manufacture Temferon.